STING1 and leukemia: Indeed, the STING agonists, TAK-676 (NCT04420884, NCT04879849) and E7766 (NCT04144140), are currently being tested clinically for the treatment of advanced or metastatic solid tumors, lymphomas, and leukemias, as adjunctive agents to conventional chemotherapy.